Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes you can.
Interesting that no reverse split was mentioned.
Good morning. I`m long since last Sept. Don`t post much anymore; but I enjoy the back and forth. I`d like to point out that ENZC is producing Mabs at multiple sites. They have spoken to the FDA about being Fast Tracked. I conclude that the Fast Track is for covid. What`s the stock do when that is announced? Why are they ready to go in Europe, Asia and Africa to supply 30 countries? Hope everyone has a terrific day. Please pray for the lives lost yesterday.
I would not be surprised if they are already licensing them out!
My theory is they`re producing Mabs because they will be fast tracked.
Thank you. Hope everyone can remember all this info.
Thanks for that. Q4 could be tremendous.
You`re welcome. ENZC is on it`s way. Reading the filing from Friday evening is very informative.
These prices are terrific for any investment clubs to load up. RSHN getting stronger " as time goes by ".
1 yr. anniversary Sept. 17th. Haven`t sold a share. I speculate some selling migrating to other stocks. Like the old song says; The other man`s grass is always greener, the sun shines brighter on the other side! For my ENZC, I see nothing but blue sky and sun.
ENZC is bid up.
I was wondering how much he owns. Nice! Thank you.
13-f from David Einhorn`s Greenlight Fund shows a new stake in Adamis Pharma
Thank you FrankMD. You passing this on is very important.
Thanks for your insight. I didn`t think Lonza would get involved with ENZC unless they stood to make plenty more than just a few million dollars off the deal. With their economies of scale; they`re looking to make hundreds of millions.
Thank so much for your time and effort.
Yes! I do remember that. I`ll try to find it. Thank you.
Thank you for that. That`s the PR that was taken down. I thought maybe there was another statement from the company saying they have a relationship with Lonza. I`ll keep looking.
Can you please show me where ENZC confirmed they are working with Lonza? I`d like to forward it to all the folks I put into ENZC. Thank you.
Could be. I do know how strong BP is. Perhaps that`s why they`re going through Europe? Good night.
Management knows they made a mistake. They don`t need us to remind them everyday. I know I`ve made mistakes at every job I`ve had. So, to harp on it everyday; does it do any good or any harm? Yes, I was upset at the time. Now I reinforce my support for them. This bump in the road won`t be repeated. It doesn`t change anything about ENZC. Best of success to us all.
ENZC has stated 2 times that they have spoken to the FDA about being put on the Fast Track. When they did this; they had to show them the science behind their request. I`m very interested in this.
Good morning and thanks for the reminder from GF. The potential here is tremendous.
Excellent summary of ENZC ownership. From your lips to God`s ear!
Look into Collagen. Types 1, 2 and 3.
Impressive. Thanks.
Thank you. I didn`t know that ADMP was a possible buy out. I`ll have to keep up moving forward. Best of success! I`ll check in later this afternoon.
Thanks. Glad to share. I was surprised by the large bids. That 150k shocked me at such a late time on a Friday. Have a great weekend.
Good morning. I like to trade in the pre and post market times. Last evening at 7:57 pm, ADMP was 1.16 bid for about 75k. All of a sudden the 1.17 stock was bought, then the 1.18 stock went, then the 1.19 stock, the 1.20 stock and finally the 1.21 stock was taken and closed there. I`ve never seen that before with only 3 minutes left to go on a Friday night. Monday could be very interesting!
Yes. They`re coming. I`m thrilled that ENZC, in an open forum, has said they have spoken with FDA 2 times regarding being fast tracked for Covid. Also, in open forums they are clearly saying they have the cure for Covid and Hiv.
Enzolytics Reports Its Progress Toward Completion Of Clinical Trials for Its ITV-1 ANTI-HIV Therapeutic and Securing Use Authorization Under the European Medicines Agency
7:30 am ET July 29, 2021 (Accesswire) Print
COLLEGE STATION, TX / ACCESSWIRE / July 29, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has completed arrangements and agreements with Danhson (https://danhson.bg/en/) and Clinic Design (https://clinicdesign.eu/) to advance its anti-HIV therapeutic ITV-1 to production and clinical trials. These steps are prefatory to approval by the European Medicines Agency (EMA), leading to patient use authorization.
Production of the therapeutic will be accomplished at Danhson pharmaceutical company facilities, to be followed by clinical trials conducted by Clinic Design. Production of the therapeutics is expected to be completed in the next few months followed by clinical trials to be conducted immediately thereafter. The protocol of the trials will be guided by Pharmalex (https://www.pharmalex.com/), an EU regulatory consulting company.
Earlier in the year, the Company announced the formation of International Medical Partners ("IMPL"), a Bulgarian Limited Liability Company, of which the Company is 50% owner. Pursuant to that formation, the Company will fund the initial production of the ITV-1 therapeutic and the Company's partners in IMBL will fund the cost of the clinical trials and cost of EMA permitting.
IMBL will be the exclusive distributor of the ITV-1 therapeutic in the European Medicines Agency member countries (namely all 27 European Union member states and Iceland, Liechtenstein and Norway) as well as the countries of Russia, Georgia, Ukraine, Moldova, Belarus, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan, Estonia, Latvia and Lithuania. IMBL may distribute the ITV-1 therapeutic outside of its exclusive territory where an exclusive license does not otherwise exist.
All documentation for registration of IMPL has been filed with the Registry Office in Sofia. The initial funding of IMBL, by Enzolytics and its partners, has been provided by the partners.
The Company's two-year audit is proceeding in accordance with GAAP requirements and will be completed and filed as soon as completed. The audit is proceeding as planned without any unanswered issues.
Harry Zhabilov, CSO of Enzolytics, stated, "We are excited about the progress we have made with the assistance of our IMBL partners. Contracting with Danhson, Clinic Design and PharmaLex is integral to the success of the EMA permitting process. As this is the second time our ITV-1 therapeutic has progressed through clinical trials and the first trials were successful, we are fully confident that we will succeed in the permitting process. With the reciprocal treaty between the EMA and FDA, we believe that the EMA approval with lead to further advancement of our ITV-1 as a successful therapy."
About Enzolytics, Inc.Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in treating HIV/AIDS. IPF is the active component of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has also been shown to modulate the immune system.
The Company is also implementing its proprietary technology to produce fully human monoclonal antibodies (mAbs) against infectious diseases, including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human monoclonal antibodies is currently being employed to produce monoclonal antibody therapeutics for numerous infectious diseases, including the Coronavirus (SARS-CoV-2) and HTLV-1.
Forward Looking StatementsThis news release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission or OTC Markets. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Certain forward-looking statements may involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC. ITV-1 is not approved by the U.S. Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of the Company to establish the efficacy of ITV-1 or its other therapeutics in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of its therapeutics in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.
Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.
I.R. contactTEN Associates, LLCTom Nelson, CEO(480) 326-8577Investor Relations Contact
Company ContactEnzolytics, Inc.2000 North Central ExpresswayPlano, TX 75074
and
Research CenterEnzolytics, Inc.Texas A&M UniversityInstitute for Preclinical StudiesCollege Station, TX 77843
SOURCE: Enzolytics, Inc.
Good morning. How is RSHN paying for these buyouts? I can`t locate that info.
Nite means nothing. Large buyers want to see large offers.
Enzolytics Announces the Appointment of Steve Sharabura as President of its Wholly Owned Subsidiary RobustoMed, Inc (A/K/A ENZO SUB)
7:30 am ET July 26, 2021 (Accesswire) Print
COLLEGE STATION, TX / ACCESSWIRE / July 26, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) ("Enzolytics" and the "Company") announced today the appointment of Steve Sharabura as President of the Company's wholly owned subsidiary RobustoMed, Inc. (A/K/A ENZO SUB) based in Atlanta, GA. RobustoMed will be initiating a new business model focused on developing international partnership opportunities for medical development stage drug and product companies. Mr. Sharabura will focus on revenue and partnership expansion in key markets worldwide, including specific initiatives in Brazil, Costa Rica and other emerging markets.
A native of Montreal, Quebec, Canada, Mr. Sharabura is also experienced in international affairs. He led technology expansion efforts with a key United Nations Agency. He has successfully sold a $10m+ new emerging technology to major telecommunications firms. Steve has 30 years of key operational and sales experiencein various technological fields, both with a series of small entrepreneurial companies and large multinational companies as well. He has previously succeeded in improving corporate productivity across a wide range of disciplines.
Steve holds a Masters of Business Administration from Cornell University and a Bachelors of Administrative Science (Economics) from the University of Western Ontario.
Charles Cotropia, CEO of Enzolytics, said: "We are pleased with the addition of Steve Sharabura to our team and look forward the benefits to be derived from the implementation of the new business model for RobustoMed. We look forward to significant growth in this new business segment."
Steve Sharabura, President of ENZC Sub, Inc., said: “Aggressive growth is our main concern and will be our main focus. I am beyond excited to make that happen.”
Right. Simple as that. I`m with you.
Dr. Chandra and our CEO Charles are using the word cure in open forums. The reason why is that we do have the CURE. Otherwise the FDA would send them a letter to cease and desist from using the word cure. This ladies and gentlemen is fact.
Yes, you make points that I`m on board with. Is MRNA worth 350.00 per share? But Bio`s are valued at what`s going on now and what`s in the pipe line. I believe that ENZC is going higher than we all think.
How about 10.00 per share for each of 20 virus we can CURE? That`s about $200.00. Still feels kind of lite though. Please everyone, do your own DD. Thanks.
You had it figured out from the beginning. Kudos to you. Glad to see you`re still around to reap the benefits of your own DD. I feel we could break out at any time now with Intel and Lonza backing.